HTFL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Heartflow Inc (HTFL) does not present a compelling buy opportunity for a beginner, long-term investor at this time. Despite strong revenue growth and a positive analyst rating, the technical indicators are bearish, options sentiment is mixed, and the stock's short-term trend suggests potential downside. Additionally, the lack of recent news or significant trading trends further limits the case for immediate investment.
The technical indicators for HTFL are bearish. The MACD histogram is negative and contracting, the RSI is neutral at 49.797, and the moving averages show a bearish alignment (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels indicate a pivot at 23.387, with resistance at 26.015 and support at 20.759. The stock's trend analysis suggests an 80% chance of a slight 0.27% increase in the next day, but a potential -7.38% decline in the next month.
The company has a strong first-mover advantage in AI-based coronary artery disease diagnostics and management. Analysts project a 20% growth rate over the next three years, driven by its FFRCT and plaque analyses. Revenue increased by 40.51% YoY in Q3 2025, and gross margin improved slightly to 76.53%.
The stock's technical indicators are bearish, and short-term trend analysis suggests potential downside. There is no recent news, significant insider or hedge fund trading activity, or congress trading data to act as a catalyst. The company remains unprofitable, with a net income of -$50.86M in Q3 2025, despite improvement YoY.
In Q3 2025, Heartflow reported revenue growth of 40.51% YoY to $46.28M. Net income improved by 165.70% YoY but remained negative at -$50.86M. EPS increased by 333.33% YoY to -1.04, and gross margin rose slightly to 76.53%. While the company is showing strong revenue growth, it remains unprofitable.
Wells Fargo initiated coverage with an Overweight rating and a $38 price target, citing strong growth potential driven by the company's FFRCT and plaque analyses. Analysts expect the company to grow at a 20% rate over the next three years.
